+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Filgrastim Market By Drug Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

  • ID: 5514617
  • Report
  • November 2021
  • Region: Global
  • 193 Pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

The Global Filgrastim Market size is expected to reach $953.4 million by 2027, rising at a market growth of 8% CAGR during the forecast period.


Filgrastim refers to the recombinant DNA-derived granulocyte colony-stimulating factor (G-CSF), which is generally utilized to cure low blood neutrophils. It is especially used in cases wherein lukapheresis is linked with rising white blood cells. In addition, there are some side effects of using filgrastim that include chest pain, hair loss, joint discomfort, and vomiting.


Filgrastim injections are utilized in the process of curing neutropenia which is a condition of having low white blood cells that can be caused by cancer medicines. This injection is a man-made form of a substance, which is naturally created in a person’s body called a colony-stimulating factor. In addition, filgrastim assists the bone marrow to develop new white blood cells. 





COVID-19 Impact Analysis

The COVID-19 pandemic has significantly impacted the workflow of the healthcare industry around the world. The disruption in the supply chain of various goods and the temporary ban on manufacturing units had a negative impact on the filgrastim market. The pandemic has increased the pressure on healthcare systems of the world. More staff and resources were reassigned to treat COVID patients who were earlier taking care of patients with a different disease.


A decline in recruitment to the trials and obstruct in the planned release of the latest oncology studies is expected to affect the filgrastim market. There are certain biosimilar developers who have also entered the market of non-biosimilar products for the development stage to find a treatment for the SAR-COV-2 virus. There are certain filgrastim biosimilars that are also utilized to cure COVID-19 infected patients.



Market Growth Factors:

Increase in the aging population

There is an increase in the geriatric population across various nations of the world, which is expected to fuel the demand for biopharmaceuticals like filgrastim biosimilars to cure the side effects caused by the treatment of numerous chronic diseases like cancer. People with the age of 65 years have surged around the world along with that age-related chronic ailments have also increased. These aged people are more vulnerable to chronic diseases.



Growing cases of chronic diseases

Chronic disease refers to a group of diseases including cardiovascular diseases, diabetes, cancer, and others. There is a rise in the number of chronic diseases among the population across the globe. Factors such as sedentary lifestyle, unhealthy diet, and consumption of tobacco are responsible for chronic diseases. Cancer is one of the top reasons behind death across the world which caused approximately 10 million deaths in 2020. Among the total number of deaths due to cancer, approx. 70% of deaths were reported in low- and middle-income countries.



Marketing Restraining Factor:

Stringent government regulations and policies

Pharmaceutical companies that are developing biosimilars like filgrastim face a major challenge in the approval process of their products. Different countries have a different process of approval for any medicine, treatment, vaccine, and medical device; however, these approval procedures are difficult to follow. It is due to the various regulations and evidence required to prove the efficacy and safety of that product.





Drug Type Outlook

Based on Drug Type, the market is segmented into Biosimilar and Biologic. Among both, the biosimilars segment is estimated to display a promising CAGR owing to the easy availability and low cost in emerging nations.



Indication Outlook

Based on Indication, the market is segmented into Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications. Among these, the chemotherapy-induced neutropenia segment acquired the highest share in the filgrastim market in 2020 and is anticipated to continue its dominance over the forecast period.



Distribution Channel Outlook

By distribution channel, the filgrastim market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Among all, the hospital pharmacies market is anticipated to witness a substantial growth during the forecast period owing to the increasing demand for filgrastim in hospitals around the world.



Regional Outlook

Region-wise, the filgrastim market is analyzed across North America, Europe, Asia Pacific, and LAMEA. North America emerged as the leading region in the filgrastim market in 2020 with the highest market share and is estimated to maintain its dominance during the forecast period. It is owing to the developed healthcare infrastructure, growing prevalence of infectious diseases, supportive reimbursement policies, and accessibility of research grants & funding.



The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd. (Kirin Company), Cadila Healthcare Ltd. (Zydus Cadila), Apotex, Inc., and Toksöz Group



Recent Strategies Deployed in Filgrastim Market

  • Nov-2021: Apobiologix, a subsidiary of Apotex introduced Bambevi. This product is utilized in combination with chemotherapy to cure specific kinds of colorectal, brain, lung, and ovarian cancer. This launch is expected to expand the Apobiologix portfolio to make sure constant support of patient requirements.
  • Jun-2021: Kyowa Kirin came into an agreement with Amgen, an American multinational biopharmaceutical company. This agreement aimed to develop and market KHK4083, Kyowa Kirin’s potential first-in-class, Phase 3-ready anti-OX40 fully human monoclonal antibody.
  • Jun-2020: Pfizer got the approval for NYVEPRIA, a biosimilar to Neulasta from the US Food and Drug Administration (FDA). This approval helps in enabling cost savings and provides better access to a crucial treatment option.
  • Nov-2019: Novartis unveiled Sandoz’s pegfilgrastim biosimilar, Ziextenzo, in the United States. Ziextenzo is used to decrease the duration of neutropenia and incidence of febrile neutropenia in adult patients cured with cytotoxic (anti-cancer) chemotherapy for malignancy with the exception of chronic myeloid leukemia and myelodysplastic syndromes.
  • Mar-2019: Apobiologix, a division of Apotex unveiled its pegfilgrastim biosimilar, Lapelga, in Canada. By availing Lapelga and Grastofil in Canada, patients can get better access to innovative, affordable, and effective biological drugs, along with providing substantial cost savings to the healthcare system.
  • Mar-2019: Pfizer received approval from the United States (U.S.) Food and Drug Administration (FDA) for TRAZIMERA, a biosimilar to Herceptin. This product is used in the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
  • Aug-2018: Teva Pharmaceutical received approval from the U.S. FDA for Granix (tbo-filgrastim) Injection. This injection is used for a new vial presentation and indication in pediatric patients one month and older. In addition, this pediatric indication and vial presentation of Granix is expected to expand the product line of treatment options, which could provide advantages for patients and healthcare providers.
  • Jul-2018: Dr. Reddy’s Laboratories released Hervycta, a biosimilar of Roche’s Herceptin, in India. This product is indicated for the treatment of HER2-positive cancers, which is expected to benefit women in India who have HER2-positive breast cancer and are required access to affordable, high-quality and innovative medicines.
  • Jul-2018: Pfizer got approval from the US FDA for NIVESTYM, a biosimilar to Neupogen. This product is for all eligible indications of the reference product. The FDA approval helped the company to expand access to critical treatment options for patients with neutropenia.
  • Dec-2017: Teva Pharmaceutical Industries got approval from South Africa’s Medicines Control Council (MCC) for the country’s first non-originator biological, filgrastim. This filgrastim is recommended as an important treatment for chemotherapy-induced febrile neutropenia and peripheral blood stem cell harvesting in autologous stem cell harvesting in haematological malignancies.
  • May-2017: Dr. Reddy’s Laboratories entered into an agreement with GE Healthcare, a subsidiary of American multinational conglomerate General Electric. Under this agreement, Dr. Reddy’s Laboratories installed FlexFactory, a manufacturing platform by GE Healthcare, to expand biologics production capabilities at its facility in Hyderabad, India.

Scope of the Study

Market Segments Covered in the Report:


By Drug Type


  • Biosimilar and
  • Biologic

By Indication


  • Chemotherapy induced Neutropenia
  • Chronic Neutropenia and
  • Other Indications

By Distribution Channel


  • Hospital Pharmacies
  • Retail Pharmacies and
  • Online Pharmacies

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:


  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksöz Group

Unique Offerings from the Publisher

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Filgrastim Market, by Drug Type
1.4.2 Global Filgrastim Market, by Indication
1.4.3 Global Filgrastim Market, by Distribution Channel
1.4.4 Global Filgrastim Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Filgrastim Market by Drug Type
3.1 Global Biosimilar Market by Region
3.2 Global Biologic Market by Region
Chapter 4. Global Filgrastim Market by Indication
4.1 Global Chemotherapy induced Neutropenia Market by Region
4.2 Global Chronic Neutropenia Market by Region
4.3 Global Other Indications Market by Region
Chapter 5. Global Filgrastim Market by Distribution Channel
5.1 Global Hospital Pharmacies Market by Region
5.2 Global Retail Pharmacies Market by Region
5.3 Global Online Pharmacies Market by Region
Chapter 6. Global Filgrastim Market by Region
6.1 North America Filgrastim Market
6.1.1 North America Filgrastim Market by Drug Type
6.1.1.1 North America Biosimilar Market by Country
6.1.1.2 North America Biologic Market by Country
6.1.2 North America Filgrastim Market by Indication
6.1.2.1 North America Chemotherapy induced Neutropenia Market by Country
6.1.2.2 North America Chronic Neutropenia Market by Country
6.1.2.3 North America Other Indications Market by Country
6.1.3 North America Filgrastim Market by Distribution Channel
6.1.3.1 North America Hospital Pharmacies Market by Country
6.1.3.2 North America Retail Pharmacies Market by Country
6.1.3.3 North America Online Pharmacies Market by Country
6.1.4 North America Filgrastim Market by Country
6.1.4.1 US Filgrastim Market
6.1.4.1.1 US Filgrastim Market by Drug Type
6.1.4.1.2 US Filgrastim Market by Indication
6.1.4.1.3 US Filgrastim Market by Distribution Channel
6.1.4.2 Canada Filgrastim Market
6.1.4.2.1 Canada Filgrastim Market by Drug Type
6.1.4.2.2 Canada Filgrastim Market by Indication
6.1.4.2.3 Canada Filgrastim Market by Distribution Channel
6.1.4.3 Mexico Filgrastim Market
6.1.4.3.1 Mexico Filgrastim Market by Drug Type
6.1.4.3.2 Mexico Filgrastim Market by Indication
6.1.4.3.3 Mexico Filgrastim Market by Distribution Channel
6.1.4.4 Rest of North America Filgrastim Market
6.1.4.4.1 Rest of North America Filgrastim Market by Drug Type
6.1.4.4.2 Rest of North America Filgrastim Market by Indication
6.1.4.4.3 Rest of North America Filgrastim Market by Distribution Channel
6.2 Europe Filgrastim Market
6.2.1 Europe Filgrastim Market by Drug Type
6.2.1.1 Europe Biosimilar Market by Country
6.2.1.2 Europe Biologic Market by Country
6.2.2 Europe Filgrastim Market by Indication
6.2.2.1 Europe Chemotherapy induced Neutropenia Market by Country
6.2.2.2 Europe Chronic Neutropenia Market by Country
6.2.2.3 Europe Other Indications Market by Country
6.2.3 Europe Filgrastim Market by Distribution Channel
6.2.3.1 Europe Hospital Pharmacies Market by Country
6.2.3.2 Europe Retail Pharmacies Market by Country
6.2.3.3 Europe Online Pharmacies Market by Country
6.2.4 Europe Filgrastim Market by Country
6.2.4.1 Germany Filgrastim Market
6.2.4.1.1 Germany Filgrastim Market by Drug Type
6.2.4.1.2 Germany Filgrastim Market by Indication
6.2.4.1.3 Germany Filgrastim Market by Distribution Channel
6.2.4.2 UK Filgrastim Market
6.2.4.2.1 UK Filgrastim Market by Drug Type
6.2.4.2.2 UK Filgrastim Market by Indication
6.2.4.2.3 UK Filgrastim Market by Distribution Channel
6.2.4.3 France Filgrastim Market
6.2.4.3.1 France Filgrastim Market by Drug Type
6.2.4.3.2 France Filgrastim Market by Indication
6.2.4.3.3 France Filgrastim Market by Distribution Channel
6.2.4.4 Russia Filgrastim Market
6.2.4.4.1 Russia Filgrastim Market by Drug Type
6.2.4.4.2 Russia Filgrastim Market by Indication
6.2.4.4.3 Russia Filgrastim Market by Distribution Channel
6.2.4.5 Spain Filgrastim Market
6.2.4.5.1 Spain Filgrastim Market by Drug Type
6.2.4.5.2 Spain Filgrastim Market by Indication
6.2.4.5.3 Spain Filgrastim Market by Distribution Channel
6.2.4.6 Italy Filgrastim Market
6.2.4.6.1 Italy Filgrastim Market by Drug Type
6.2.4.6.2 Italy Filgrastim Market by Indication
6.2.4.6.3 Italy Filgrastim Market by Distribution Channel
6.2.4.7 Rest of Europe Filgrastim Market
6.2.4.7.1 Rest of Europe Filgrastim Market by Drug Type
6.2.4.7.2 Rest of Europe Filgrastim Market by Indication
6.2.4.7.3 Rest of Europe Filgrastim Market by Distribution Channel
6.3 Asia Pacific Filgrastim Market
6.3.1 Asia Pacific Filgrastim Market by Drug Type
6.3.1.1 Asia Pacific Biosimilar Market by Country
6.3.1.2 Asia Pacific Biologic Market by Country
6.3.2 Asia Pacific Filgrastim Market by Indication
6.3.2.1 Asia Pacific Chemotherapy induced Neutropenia Market by Country
6.3.2.2 Asia Pacific Chronic Neutropenia Market by Country
6.3.2.3 Asia Pacific Other Indications Market by Country
6.3.3 Asia Pacific Filgrastim Market by Distribution Channel
6.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
6.3.3.2 Asia Pacific Retail Pharmacies Market by Country
6.3.3.3 Asia Pacific Online Pharmacies Market by Country
6.3.4 Asia Pacific Filgrastim Market by Country
6.3.4.1 China Filgrastim Market
6.3.4.1.1 China Filgrastim Market by Drug Type
6.3.4.1.2 China Filgrastim Market by Indication
6.3.4.1.3 China Filgrastim Market by Distribution Channel
6.3.4.2 Japan Filgrastim Market
6.3.4.2.1 Japan Filgrastim Market by Drug Type
6.3.4.2.2 Japan Filgrastim Market by Indication
6.3.4.2.3 Japan Filgrastim Market by Distribution Channel
6.3.4.3 India Filgrastim Market
6.3.4.3.1 India Filgrastim Market by Drug Type
6.3.4.3.2 India Filgrastim Market by Indication
6.3.4.3.3 India Filgrastim Market by Distribution Channel
6.3.4.4 South Korea Filgrastim Market
6.3.4.4.1 South Korea Filgrastim Market by Drug Type
6.3.4.4.2 South Korea Filgrastim Market by Indication
6.3.4.4.3 South Korea Filgrastim Market by Distribution Channel
6.3.4.5 Singapore Filgrastim Market
6.3.4.5.1 Singapore Filgrastim Market by Drug Type
6.3.4.5.2 Singapore Filgrastim Market by Indication
6.3.4.5.3 Singapore Filgrastim Market by Distribution Channel
6.3.4.6 Malaysia Filgrastim Market
6.3.4.6.1 Malaysia Filgrastim Market by Drug Type
6.3.4.6.2 Malaysia Filgrastim Market by Indication
6.3.4.6.3 Malaysia Filgrastim Market by Distribution Channel
6.3.4.7 Rest of Asia Pacific Filgrastim Market
6.3.4.7.1 Rest of Asia Pacific Filgrastim Market by Drug Type
6.3.4.7.2 Rest of Asia Pacific Filgrastim Market by Indication
6.3.4.7.3 Rest of Asia Pacific Filgrastim Market by Distribution Channel
6.4 LAMEA Filgrastim Market
6.4.1 LAMEA Filgrastim Market by Drug Type
6.4.1.1 LAMEA Biosimilar Market by Country
6.4.1.2 LAMEA Biologic Market by Country
6.4.2 LAMEA Filgrastim Market by Indication
6.4.2.1 LAMEA Chemotherapy induced Neutropenia Market by Country
6.4.2.2 LAMEA Chronic Neutropenia Market by Country
6.4.2.3 LAMEA Other Indications Market by Country
6.4.3 LAMEA Filgrastim Market by Distribution Channel
6.4.3.1 LAMEA Hospital Pharmacies Market by Country
6.4.3.2 LAMEA Retail Pharmacies Market by Country
6.4.3.3 LAMEA Online Pharmacies Market by Country
6.4.4 LAMEA Filgrastim Market by Country
6.4.4.1 Brazil Filgrastim Market
6.4.4.1.1 Brazil Filgrastim Market by Drug Type
6.4.4.1.2 Brazil Filgrastim Market by Indication
6.4.4.1.3 Brazil Filgrastim Market by Distribution Channel
6.4.4.2 Argentina Filgrastim Market
6.4.4.2.1 Argentina Filgrastim Market by Drug Type
6.4.4.2.2 Argentina Filgrastim Market by Indication
6.4.4.2.3 Argentina Filgrastim Market by Distribution Channel
6.4.4.3 UAE Filgrastim Market
6.4.4.3.1 UAE Filgrastim Market by Drug Type
6.4.4.3.2 UAE Filgrastim Market by Indication
6.4.4.3.3 UAE Filgrastim Market by Distribution Channel
6.4.4.4 Saudi Arabia Filgrastim Market
6.4.4.4.1 Saudi Arabia Filgrastim Market by Drug Type
6.4.4.4.2 Saudi Arabia Filgrastim Market by Indication
6.4.4.4.3 Saudi Arabia Filgrastim Market by Distribution Channel
6.4.4.5 South Africa Filgrastim Market
6.4.4.5.1 South Africa Filgrastim Market by Drug Type
6.4.4.5.2 South Africa Filgrastim Market by Indication
6.4.4.5.3 South Africa Filgrastim Market by Distribution Channel
6.4.4.6 Nigeria Filgrastim Market
6.4.4.6.1 Nigeria Filgrastim Market by Drug Type
6.4.4.6.2 Nigeria Filgrastim Market by Indication
6.4.4.6.3 Nigeria Filgrastim Market by Distribution Channel
6.4.4.7 Rest of LAMEA Filgrastim Market
6.4.4.7.1 Rest of LAMEA Filgrastim Market by Drug Type
6.4.4.7.2 Rest of LAMEA Filgrastim Market by Indication
6.4.4.7.3 Rest of LAMEA Filgrastim Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview

Companies Mentioned

  • Abbott Laboratories
  • Amgen, Inc.
  • Pfizer, Inc.
  • Novartis AG
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Kyowa Kirin Co., Ltd. (Kirin Company)
  • Cadila Healthcare Ltd. (Zydus Cadila)
  • Apotex, Inc.
  • Toksöz Group

Methodology

Loading
LOADING...